Joseph Frattaroli, Chief Financial Officer at Inhibikase Therapeutics, Inc. (IKT), bought 3,948 shares at $0.64 ($3K) on 2022-05-19, disclosed to the SEC on 2022-05-23.
Open-market purchase of $3k IKT by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.